The call for proposals is now closed to new applications.
You can check the status of your application by clicking “My Proposals” and logging into your accounts.


Africa NCD Open Lab




Conditions for applicants


  • Applications must be completed in English.
  • Abbreviations should not be used in the application unless fully explained.
  • Applications will only be accepted via the application portal.
  • The closing date will be 4pm GMT (UK time) on Thursday the 12th of January 2017. Applications received after this date will not be considered.
  • The outcome of the selection of funded proposals will be final, binding and not open to appeal.
  • The grant can be used to fund direct costs related to the project only, which includes costs for equipment, field work and data collection, consumables and research assistance, travel to conferences, subsistence and conference fees.
  • Costs for principal applicant’s salary are not included in this grant as it is assumed that they hold a salaried position in their institution. The applicant’s institution may however be eligible in some cases to apply for ‘lecturer or clinician buy-out time’ to cover for dedicated research time for the applicant. This will be negotiated on a case-by-case basis with the institution involved.
  • Institutions may request overhead costs, not exceeding 8% of direct costs
  • The principal applicant’s institution will be responsible for the receipt and administration of all funds.
  • All costs must be reasonable and justified and will ultimately be awarded at the discretion of GSK.
  • The grant can only be used to deliver the objectives stated in the grant application.
  • The grant may be used to contract out elements of the work where required, however the grantee is not permitted to make sub-grants.
  • The maximum term of the grant is two years from the date of agreement being signed. There is no minimum term.
  • Grants are made on the basis that the grantee commits to conduct all work to the relevant applicable global standard including but not limited to: Declaration of Helsinki, ICH GCP, ICH GMP and all locally relevant regulations.
  • Approved grants will have funds released in stages as required, in response to successful completion of prior stages of research and achievement of milestones.
  • Grantees must maintain transparent, adequate records to track use of the funds provided and the results recorded from the research.
  • Grantees are expected to publish research findings in quality peer-reviewed journals
  • Applications will only be accepted from applicants working in Cameroon, Cote D’Ivoire, Ethiopia, Ghana, Gambia, Kenya, Malawi, Nigeria, Uganda, Senegal and Tanzania. However, collaborations with centres outside of the applicant’s country but within sub-Saharan Africa are encouraged.
  • Each applicant can only submit one application. Multiple applications can however be submitted by an institution.
  • Applications must be for work programmes that are lawful in the country in which the work will be carried out.
  • Depending on the intellectual contribution associated with the proposal, successful grantees will be expected to sign a collaboration agreement with GSK which will be based on the relevant Lambert Agreement (or similar), as described at http://www.ipo.gov.uk/Lambert, with the further intention that results of the collaboration are shared for the broader benefit of the research community.
  • Applications must not be submitted for research which would breach the intellectual property rights of other parties.
  • Applicants agree that GSK may share the personal information submitted by the applicants and all other information submitted in application proposals, with third parties around the world in order to process and review the application to assess suitability for a grant.
  • Applicants confirm that they have all required permissions from third parties (including the research institution where the proposed research may be carried out and the proposed local supervisor/mentor in the event of a successful application) in order to submit the information provided in support of the application.



Terms of use Accessibility Cookie policy Privacy
© 2001-2017 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.